ArticleNature genetics2018
Genome-scale analysis identifies paralog lethality as a vulnerability of chromosome 1p loss in cancer.
Abstract read
In one paragraph
Article in Nature genetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed.
- Context-dependent synthetic lethality - an emerging precision therapeutic approach.Nature reviews. Cancer · 2026Review
- Article
- Article
- Phenotypic screening converges on CDK9 inhibition as a therapeutic strategy in translocation renal cell carcinoma.bioRxiv : the preprint server for biology · 2025Article
- Incomplete paralog compensation generates selective dependency on TRA2A in cancer.PLoS genetics · 2025Article
- Oncogenic TFE3 fusions drive OXPHOS and confer metabolic vulnerabilities in translocation renal cell carcinoma.Nature metabolism · 2025Article
- Article
- Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers.Cancer research communications · 2025Article
- Ibetazol, a novel inhibitor of importin β1-mediated nuclear import.Communications biology · 2024Article
- A framework for target discovery in rare cancers.bioRxiv : the preprint server for biology · 2024Article
- Aneuploidy as a driver of human cancer.Nature genetics · 2024Review
- Patterns of Aneuploidy and Signaling Consequences in Cancer.Cancer research · 2024Review
- TFE3 fusions direct an oncogenic transcriptional program that drives OXPHOS and unveils vulnerabilities in translocation renal cell carcinoma.bioRxiv : the preprint server for biology · 2024Article
- Mitoferrin2 is a synthetic lethal target for chromosome 8p deleted cancers.Genome medicine · 2024Article
- MAGOH promotes gastric cancer progression via hnRNPA1 expression inhibition-mediated RONΔ160/PI3K/AKT signaling pathway activation.Journal of experimental & clinical cancer research : CR · 2024Article
- Article
- Nuclear transport proteins: structure, function, and disease relevance.Signal transduction and targeted therapy · 2023Review
- MAGOH is correlated with poor prognosis and is essential for cell proliferation in lower-grade glioma.Aging · 2023Article
- Paralog-based synthetic lethality: rationales and applications.Frontiers in oncology · 2023Review
- The paralogues MAGOH and MAGOHB are oncogenic factors in high-grade gliomas and safeguard the splicing of cell division and cell cycle genes.RNA biology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Srinivas R ViswanathanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Marina F NogueiraDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-3143-9799
Colin G BussHarvard-MIT Department of Health Sciences and Technology, Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Boston, MA, USA.ORCID http://orcid.org/0000-0001-7771-1685
John M Krill-BurgerBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Mathias J WawerChemical Biology and Therapeutics Science Program, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Edyta MalolepszaBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Ashton C BergerDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Peter S ChoiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Juliann ShihBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-4086-8651
Alison M TaylorDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Benjamin TanenbaumBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-7803-3839
Chandra Sekhar PedamalluDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Andrew D CherniackBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-0470-0111
Pablo TamayoBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-9360-4668
Craig A StrathdeeBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Kasper LageBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Steven A CarrBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Monica SchenoneBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-6456-8768
Sangeeta N BhatiaBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Francisca VazquezBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Aviad TsherniakBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-3797-1877
William C HahnDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-2840-9791
Matthew MeyersonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. matthew_meyerson@dfci.harvard.edu.ORCID http://orcid.org/0000-0002-9133-8108
Funding
VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Jacqueline A. Lees · 1985 to 2026
$93.9MTOXICOLOGY CORE UNITP30ES002109 · NIEHS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LEVINE, STUART S · 1985 to 2020
$25.6MPhysician Scientist Training in Cancer ResearchT32CA009172 · NCI · DANA-FARBER CANCER INSTITUTE · PI Jennifer R Brown, James A. DeCaprio · 1985 to 2026
$17.1MNKX2-1 Enhancer Amplification and Lineage Addiction in Lung AdenocarcinomaR35CA197568 · NCI · DANA-FARBER CANCER INST · PI Matthew L. Meyerson · 2015 to 2026
$12.4MThe Dana-Farber Cancer Institute Cancer Target Discovery and Development CenterU01CA176058 · NCI · DANA-FARBER CANCER INST · PI HAHN, WILLIAM C. · 2013 to 2021
$7.8MA Rational Systematic Approach to Find Combinations of Pharmacologic and Immune Therapies that Target Identifiable Oncogenic StatesU01CA217885 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI COHEN, EZRA, KAUFMAN, DAN S. · 2017 to 2021
$5.1MNext-generation Functional Genetic Screening of Un-screenable TraitsR01HG009285 · NHGRI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MALI, PRASHANT, TAMAYO, PABLO · 2017 to 2020
$4.2MGenePattern Notebooks for Cancer ResearchU24CA194107 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MESIROV, JILL P. · 2015 to 2019
$2.8MSystematic mapping of genetic vulnerabilities in head and neck cancerR01CA222826 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MALI, PRASHANT · 2018 to 2022
$1.8MDissecting the interplay of gene regulatory networks and cellular niche on cell fate determinationR01GM123313 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MALI, PRASHANT · 2018 to 2021
$1.2MInvestigating the role of RBM10-regulated alternative splicing in lung tumorigenesisK99CA208028 · NCI · DANA-FARBER CANCER INST · PI CHOI, PETER S. · 2016 to 2017
$266kNCI NIH HHS K99 CA208028NCI NIH HHS P30 CA014051NCI NIH HHS R01 CA222826NCI NIH HHS R35 CA197568NCI NIH HHS T32 CA009172NCI NIH HHS U01 CA176058NCI NIH HHS U01 CA217885NCI NIH HHS U24 CA194107NHGRI NIH HHS R01 HG009285NIEHS NIH HHS P30 ES002109NIGMS NIH HHS R01 GM123313
Abstract
Functional redundancy shared by paralog genes may afford protection against genetic perturbations, but it can also result in genetic vulnerabilities due to mutual interdependency
Indexed as
Chromosomes, Human, Pair 1AnimalsCell Line, TumorCell NucleusExonsFemaleGene DeletionHEK293 CellsHumansKaryopherinsMiceMice, NudeNeoplasmsNuclear ProteinsRNA, Small InterferingRNA SplicingKaryopherinsNuclear ProteinsRNA, Small Interfering
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.